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A gold(III) pincer ligand scaffold for the synthesis of binuclear 
and bioconjugated complexes: synthesis and anticancer potential 
Benoît Bertrand,[a], [c]* Maria A. O’Connell,[b] Zoë A. E. Waller,[b] and Manfred Bochmann[a]
Abstract: Cyclometalated (C^N^C)Au(III) complexes bearing 
functionalized N-heterocyclic carbene (NHC) ligands provide a high-
yielding, modular route to bioconjugated and binuclear complexes.  
This methodology has been applied to the synthesis of 
bioconjugated complexes presenting biotin and 17α-ethynylestradiol 
vectors, as well as to the synthesis of bimetallic Au(III)/Au(I) 
complexes. The in vitro antiproliferative activities of these 
compounds against various cancer cells lines depend on the linker 
length, with the longer linker being the most potent. The estradiol 
conjugate AuC6Estra proved to be more toxic against the estrogen 
receptor positive (ER+) cancer cells than against the ER- cancer 
cells and non-cancer cells. The bimetallic complex AuC6Au was 
more selective for breast cancer cells with respect to a healthy cell 
standard than the monometallic complex AuNHC. The metal uptake 
study on cells expressing or not biotin and estrogen receptors 
revealed an improved and targeted delivery of gold for both the 
bioconjugated complexes AuC6Biot and AuC6Estra compared to 
the non-vectorised analogue AuNHC. The investigations of the 
interaction of the bioconjugates and bimetallic complexes with 
human telomeric G-quadruplex DNA using FRET-melting techniques 
revealed a reduced ability to stabilize this DNA structure with respect 
to the non-vectorised analogue AuNHC. 
 
Introduction 
 
Cyclometallated Au(III) complexes have attracted significant interest 
in the last decade for a large palette of applications including 
fundamental gold chemistry investigations,
[1]
 photoemissive 
materials
[2]
 and biological applications.
[3]
 Bis-cyclometallated 
(C^N^C)Au(NHC) complexes have appeared as particularly 
promising anticancer agents (see Figure 1 for examples).
[4]
  
Those complexes have been indicated to enhance 
topoisomerase 1 induced DNA cleavage,
[4a]
 to downregulate protein 
synthesis pathways
[4c]
 and to stabilize G-quadruplex and i-motif 
structures in DNA (Figure 1, type A and B).
[5]
 We have demonstrated 
that a pyrazine-based [(C^N
pz
^C)Au(NHC)]
+
 complex (AuNHC in 
Figure 1), which presents low- to sub-micromolar IC50 values on 
various cancer cell lines, was highly stable toward reduction and 
substitution in physiological environments, even in the presence of 
glutathione. However, its low selectivity for cancer cells with respect 
to healthy ones remains a challenge.
[5]
 Modifying the NHC ligand in 
structure B (Figure 1), e.g. by decorating substituents R
1
, R
2
 with 
suitable vectors, seemed a promising strategy to improve the 
selectivity for cancer cells and to decrease potential side effects. 
Conjugation to biological vectors and use of polynuclear compounds 
have been shown to lead to increases in the selectivity and toxicity 
of anticancer drugs.
[6,7,8,9]
 To this end, we recently investigated the 
synthesis of amino ester-decorated (C^N
pz
^C)Au(III) acyclic carbene 
complexes (Figure 1, type C), made by the nucleophilic attack by the 
corresponding amino esters on cationic (C^N
pz
^C)Au(III) isocyanide 
complexes. However, although that methodology was successful 
when using amino esters, the requirement to work under perfectly 
anhydrous conditions precluded the use of more elaborate 
biomolecules. Moreover, those acyclic carbene complexes were 
found to be much less stable toward GSH than cyclic NHC-based 
complexes.
[10]
  
Imidazole- and benzimidazole-type NHC ligands bearing 
pentafluorophenol ester moieties have already been successfully 
used for grafting organometallic Ru(II) and Au(I) complexes onto 
peptides,
[11]
 aptamers
[12]
 and for the synthesis of bimetallic 
complexes.
[13]
 The synthesis of bioconjugated metal complexes often 
requires considerable synthetic efforts in order to achieve modularity 
in terms of potential vectors and also in terms of linkers between the 
pharmacophore and the vector.
[14]
 Thus, using an NHC ligand 
featuring a pentafluorophenol ester group to build a single scaffold 
for the bioconjugation of different vectors or metal-based fragment 
onto a (C^N
pz
^C)Au(III) core could lead to large library of biologically 
relevant compounds in only few synthetic steps.
 
Figure 1: Examples of [(C^N^C)Au(NHC)]
+
 complexes investigated 
for anticancer purposes.
[4a,5,10] 
 
Here we report a high-yield three-step procedure for the synthesis of 
bioconjugated and bimetallic complexes using a common 
[(C^N
pz
^C)Au(NHC)]
+
 precursor complex of type B bearing a 
pentafluorophenyl ester group on the NHC ligand. We used this 
precursor for the synthesis of biotin, 17α-ethynylestradiol and 
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benzimidazole-based (NHC)AuCl conjugates connected by linkers of 
variable length. The different conjugates and bimetallic complexes 
have been investigated in vitro for their antiproliferative properties on 
human cancer cell lines. 
 
 
Results and Discussion 
Synthesis and characterization. The synthetic route is shown in 
Scheme 1. Complex 2 was obtained in 70% yield by the classical 
transmetallation method, starting by reacting the benzimidazolium 
salt with silver oxide to afford the silver-NHC complex, followed by 
NHC transfer to (C^N
pz
^C)AuCl. The reaction of 2 with 
diaminoalkanes of different chain lengths (i. e. ethylenediamine, 1,4-
diaminobutane, and 1,6-diaminohexane) in refluxing acetonitrile 
gave high isolated yields of the corresponding [(C^N
pz
^C)Au(NHC)]
+
 
derivatives with pendent amine substituents, AuCnNH2 (n = 2, 4, 6) 
(Scheme 1). The 
19
F{
1
H} NMR spectra confirmed the quantitative 
conversion of the pentafluorophenol group. The 
1
H NMR spectra 
showed the loss of symmetry of the various diaminoalkyl linkers 
associated with the lower frequency shift of the signals of the 
benzylic protons due to the increase of electron density upon 
substitution of the pentafluorophenol ester by an amine. In the 
AuCnNH2 complexes, the 
13
C{
1
H} NMR C=O signals are shifted from 
δ 161 ppm in 2 to 165-166 ppm in the amide products, depending of 
the length of the alkyl chain. Amide formation was further 
corroborated by the shift of the ν(C=O) band in the IR spectra from 
1760 cm
-1
 to 1650 cm
-1
. All these features are in good agreement 
with reported reactions.
[13] 
 
 
Scheme 1: Synthesis of the complexes AuCnNH2 (n = 2, 4, 6). 
 
The AuCnNH2 complexes were converted to bioconjugated 
and binuclear complexes as shown in Scheme 2. Biotin has already 
been used for the targeting of taxol
[15]
 and metal complexes.
[4c,16]
 To 
obtain gold(III) biotin conjugates, AuCnNH2 complexes were reacted 
with the biotin-N-hydroxysuccinimide (biotin-NHS) precursor 3 at 
room temperature for 24 hours. Precipitation with Et2O afforded the 
Au(III)/biotin conjugates AuCnBiot (n = 2, 4, 6) in almost quantitative 
isolated yields. The success of the reactions was confirmed by 
1
H 
NMR spectroscopy which showed a 1/1 ratio between the signals of 
the biotin and [(C^N
pz
^C)Au(NHC)]
+
 fragment, coupled with the 
disappearance of the NHS signal and the appearance of a signal of 
a second amide proton. The IR spectra of the AuCnBiot complexes 
displayed two ν(C=O) bands at 1704 cm
-1
 and 1646 cm
-1
 
corresponding, respectively, to the urea and amide functional groups. 
The formation of the expected conjugates was further confirmed by 
high resolution mass spectrometry, which showed in each case the 
molecular monocation and the dicationic adducts with sodium or 
potassium. 
Estradiol/metal complex conjugates have been used to target 
estrogen receptor positive (ER+) cells.
[14a,17]
 By reacting the 
AuCnNH2 complexes with the 17α-ethynylestradiol-NHS precursor 4 
at room temperature in acetonitrile in presence of a base, the 
Au(III)/estradiol conjugates AuCnEstra (n = 2, 4, 6) were obtained in 
good isolated yield (Scheme 2). Those yields were more than 25% 
higher than the previously reported coupling methods between 
metal-NHC complexes and estradiol derivatives using ruthenium-
catalyzed alkyne-azide cycloaddition.
[17a]
 The formation of the 
bioconjugated species was indicated in the 
1
H NMR spectrum by the 
1/1 ratio of the signals for the [(C^N
pz
^C)Au(NHC)]
+
 core and the 
estradiol vector, together with the disappearance of the signal of the 
NHS group. IR spectroscopy showed in all cases only one signal for 
the carbonyl function, as previously seen for the biotin conjugates. 
The formation of the expected conjugates was also confirmed by 
high resolution mass spectrometry, which in each case showed the 
molecular cation. 
Few studies have reported mixed valence Au(I)/Au(III) 
complexes and, to the best of our knowledge, never with organogold 
fragments.
[18]
 By reacting the AuCnNH2 complexes with the Au(I)-
NHC precursor 5 in acetonitrile at room temperature, the mixed 
valence binuclear complexes AuCnAu (n = 2, 4, 6) were obtained 
with very high isolated yields (Scheme 2). The 
1
H NMR spectra of 
the binuclear complexes displayed a 1/1 ratio between the signals of 
the Au(III) and Au(I) fragments, a signal for a second amide proton 
and the quasi-equivalence of the two CH2 groups in α position with 
respect to the amides. The 
13
C{
1
H} NMR spectra of the AuCnAu 
complexes showed two different carbene-C signals at δ 179 and 163 
ppm for the Au(I)-NHC and Au(III)-NHC fragments, respectively. 
These signals were identified using 
1
H-
13
C 2D-NMR spectroscopy 
which showed the correlation between the methyl and methylene 
side-chain of each carbene with the corresponding carbene-C 
signals (Figure 2). The formation of the expected bimetallic 
complexes was also confirmed by high resolution mass spectrometry 
which showed in each case the molecular monocation and the 
dication resulting from the loss of the chloride ligand. 
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Scheme 2: Synthesis of the bioconjugated complexes AuCnBiot and AuCnEstra (n = 2, 4, 6) and the binuclear complexes AuCnAu (n = 2, 4, 
6). 
 
 
 
Figure 2: HMBC 
1
H-
13
C
 
2D correlation spectra of AuC2Au showing 
the two different NHC-Au
I/III
 moieties. Spectra recorded in CD2Cl2 at 
298 K. 
Evaluation of antiproliferative activity. All conjugated and binuclear 
compounds were screened at concentrations of 100 µM and 10 µM 
against MCF-7 cells, which are known to express both biotin and 
estrogen receptors.
[14a,15]
 Cell viability was measured after 72 hours 
of incubation by the classical MTS assay (see Experimental Section). 
The results are depicted in Figure 3. 
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Figure 3: Inhibition of MCF-7 cells proliferation by complexes A) 
AuCnBiot (n = 2, 4, 6); B) AuCnEstra (n = 2, 4, 6); C) AuCnAu (n = 
2, 4, 6). Data represent the average ± standard deviation of three 
experiments. The significance of the results was analysed by t-test. 
*p value < 0.05; **p value < 0.01; ***p value < 0.001. 
 
The data show a correlation between the length of the alkyl linker 
and the toxicity of the respective systems, with the C6 complexes 
being significantly more toxic than the C2 and C4 congeners, except 
for the AuCnAu complexes where the difference between the C6 and 
C4 compounds is not significant. For that reason AuC6Biot, 
AuC6Estra and AuC6Au were selected for further cytotoxic 
investigations. The complexes AuC6Biot and AuC6Estra were 
tested on panels of cells expressing or not expressing biotin 
receptors (BR) and estrogen receptors (ER), respectively. Tests on 
normal healthy fibroblasts were included for comparison. Results are 
reported in Table 1.  
 The antiproliferative profile of AuC6Biot does not seem to 
depend on the expression of the biotin receptors (Table 1). Indeed, 
AuC6Biot appeared only marginally more potent against some of the 
BR+ cell lines (MCF-7 and MDA-MB-231) than against BR- cell lines 
(HCT-116 and HEK-293) or the healthy fibroblasts (MRC5) (IC50 = 
8.9 ± 0.7; 9.6 ± 1.6; 11.2 ± 0.9; 10.3 ± 0.4 and 11 ± 5 μM against 
MCF-7, MDA-MB-231, HCT-116, HEK-293 and MRC-5 cells 
respectively). The introduction of the polar biotin substituent into the 
NHC framework greatly reduced the cytotoxicity, e.g. against MCF-7 
by a factor of ~16 compared to AuNHC. Moreover AuC6Biot 
appeared completely non-toxic against A549 cells although these 
are reported to largely express biotin receptors.
[15]
  
 A different situation was encountered in the case of 
AuC6Estra. This complex was tested against MCF-7 (ER+), MDA-
MB-231 (ER-) and MRC-5 (healthy fibroblasts) cells (Table 1). The 
antiproliferative effect of AuC6Estra against the ER+ cells was 
slightly higher than against the ER- and non-cancer cells. This may 
suggest a possible targeting effect of the 17α-ethynylestradiol 
vector. 
Interestingly, AuC6Au presented a specificity for the breast 
cancer cell lines MCF-7 and MDA-MB-231 (IC50 = 13.7 ± 2.2 and 9.2 
± 2.9 μM, respectively) compared to the other cancer cells A549 
(lung) and HCT116 (colon) (IC50 > 100 μM in both cases) (Table 1). 
AuC6Au showed the same ratio between its IC50 values against 
MCF-7 cells and healthy fibroblasts (IC50 = 38.1 ± 5.7 μM) as 
AuNHC. Moreover, the IC50 value of AuC6Au was four times lower 
against MDA-MB-231 cells than against MRC-5 cells. This contrasts 
with the unsubstituted Au(III) complex AuNHC which proved four 
times more toxic against healthy fibroblasts than against MDA-MB-
231 cells. The results demonstrate a promising increase in anti-
cancer selectivity as a result of NHC modification. 
 
 
 
Table 1: Comparison of the effects of AuC6Biot, AuC6Estra, AuC6Au and AuNHC on cell viability of a panel of human cancer cell lines, of 
human embryonic kidney HEK-293 cells and of healthy fibroblast MRC-5 cells after 72 h incubation. 
Cell line 
receptor 
expression
[14a,15] 
IC50 (μM)
a
 
AuC6Biot AuC6Estra AuC6Au AuNHC 
MCF-7 ER+/BR+ 8.9 ± 0.7 5.9 ± 0.4
 
13.7 ± 2.2 0.56 ± 0.02
5
 
MDA-MB-231 ER-/BR+ 9.6 ± 1.6 9.3 ± 1.2
 
9.2 ± 2.9 5.7 ± 0.4
10
 
A549 BR+ > 100 n. d. > 100 7.8 ± 1.3
5
 
HCT-116 BR- 11.2 ± 0.9 n. d. > 100 11.2 ± 1.5
10
 
HEK-293 BR- 10.3 ± 0.4 n. d. n. d. 5.2 ± 0.3 
MRC-5 n. d. 11 ± 5 9.1 ± 0.6
 
38.1 ± 5.7 1.4 ± 0.4
5
 
a
 Data represent the average ± standard deviation of three experiments. n. d.: not determined.  
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.Cellular gold uptake. Drug uptake and intracellular metal 
accumulation has been demonstrated to be one of the main factors 
limiting drug efficacy.
[19]
 The role of biovectors on the uptake of 
metal-based drugs can be quantified using inductively coupled 
plasma-mass spectrometry techniques (ICP-MS); this method has 
already been used in order to assess the role of biovectors on the 
uptake of metal-based drugs.
[20]
 We investigated the impact of the 
vectors and the presence of a second gold centre on the 
accumulation of our complexes by measuring the gold uptake in 
MCF-7 cells (ER+ and BR+), HCT-116 (BR-) and MDA-MD-231 (ER-
). The results are depicted in Figure 4. 
 
Figure 4: Impact of the vector and second gold center on the cell 
uptake by A) MCF-7 (BR+) and HCT-116 (BR-) cells; B) MCF-7 
(ER+) and MDA-MB-231 (ER-) cells after 6 hours of treatment with 
10 µM of compounds in DMSO; data represent the average and 
standard deviations of three experiments. The significance of the 
results was analyzed by t-test. *p value < 0.05; **p value < 0.01. 
 
Interestingly, both the biotin and 17α-ethynylestradiol vector 
improved the gold uptake with respect to the non-conjugated 
complex AuNHC. Moreover, for both AuC6Biot and AuC6Estra the 
cells expressing the corresponding receptors (BR for AuC6Biot and 
ER for AuC6Estra) presented a significantly higher intracellular gold 
content than the cells not expressing the receptors. This suggests 
the potential of using such vectors to effectively and selectively 
deliver metal-based compounds to selected cancer cells. However, 
despite the enhanced intracellular accumulation, both AuC6Biot and 
AuC6Estra appeared less cytotoxic than AuNHC, which suggests 
that cell uptake might not be the limiting factor for those compounds. 
In contrast, despite having two gold atoms per molecule, AuC6Au 
showed a reduced intracellular concentration of gold in all cancer 
cells with respect to the mono-gold complex AuNHC. This is in line 
with the reduced antiproliferative activity of AuC6Au. Moreover, 
AuC6Au presented a significantly reduced gold uptake in HCT-116 
cells where it demonstrated no antiproliferative activity. 
 
Interaction with DNA G-quadruplex. G-quadruplexes are secondary 
structures of DNA formed by stacking of tetrads of guanines 
residues linked via Hoogsteen hydrogen-bonding and stabilized by 
the presence of typically monovalent cations in the center of the 
tetrad.
[21]
 We recently reported on the ability of AuNHC to stabilize 
the G-quadruplex structure of DNA as a possible intracellular target 
for these class of compounds.
[5]
 To highlight the impact of the 
vectors and the second gold centre on the interaction of the 
[(C^N
pz
^C)Au(NHC)]
+
 core with potential targets, AuC6Biot, AuC6Au, 
AuC6Estra and AuC6NH2 were screened against the human 
telomeric G-quadruplex sequence (5ʹ-GGG-TTA-GGG-TTA-GGG-
TTA-GGG-3ʹ, hTeloG) at pH 7.2 by a FRET-based DNA melting 
assay (see Experimental). The results are presented in Figure 5.
 
 
Figure 5: Stabilization of human telomeric DNA G-quadruplex 
sequence (hTeloG, 0.2 µM) in 10 mM socium cacodylate, 100 mM 
NaCl at pH 7.2 by complexes AuNHC, AuC6NH2, AuC6Biot, 
AuC6Au and AuC6Estra at 1 µM measured by FRET-DNA melting 
assay; data represent the average and standard deviations of three 
experiments. The significance of the results was analyzed by t-test. 
**p value < 0.01; ***p value < 0.001. 
 
Compared to the parent compound, AuNHC, we could observe a 
reduced interaction with hTeloG due to the presence of the long 1,6-
diaminohexane linker (ΔTm = 3.6 ± 0.8°C for AuC6NH2). Furthermore 
the presence of the two vectors reduced even more the interaction 
with hTeloG with respect to AuC6NH2 (ΔTm = 1.6 ± 0.6; 1.4 ± 0.6°C 
for AuC6Biot and AuC6Estra respectively). Interestingly, although 
NHC-Au(I)-Cl compounds have been reported not to stabilize G-
quadruplex structures,
[22]
 the presence of the second gold centre 
enhanced the interaction with hTeloG with respect to AuC6NH2 (ΔTm 
= 6.0 ± 0.3°C for AuC6Au) and was close to the strength of the 
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interaction between AuNHC and hTeloG (ΔTm = 8.1 ± 0.7°C for 
AuNHC). Overall, these data suggest, at least for the example of the 
G-quadruplex DNA structures, that whilst the presence of either the 
biotin or the 17α-ethynylestradiol improved the uptake of 
[(C^N
pz
^C)Au(NHC)]
+
 , at the same time they decreased the ability of 
the [(C^N
pz
^C)Au(NHC)]
+
 core to interact with a possible intracellular 
target. This inhibition of interaction may be correlated with the 
observed decreased antiproliferative activity. On the contrary, having 
a second gold centre does not dramatically reduce the interaction 
with the target but decreased the cell uptake, resulting also in a 
generally reduced antiproliferative activity. 
 
Conclusions 
 
In summary, the synthesis of a library of bioconjugated and binuclear 
[(C^N
pz
^C)Au(NHC)]
+
 complexes has been achieved in high yields 
employing a modular approach from a common Au(III) scaffold. This 
has allowed the easy screening of several molecular design 
parameters such as the linker length, the biological vector used and 
the number of metal centres. While the biotin and 17α-
ethynylestradiol vectors improved and targeted the gold uptake to 
cells expressing the relevant receptors, they did not increase the 
antiproliferative activities, likely due to a reduction in the interaction 
of these sterically more hindered complexes with possible 
intracellular targets. By contrast, the reduced activity of the bimetallic 
complex AuC6Au was mainly driven by a reduced intracellular 
accumulation. On the other hand, AuC6Au was up to 4.1 times more 
toxic towards MDA-MB-231 cancer cells than towards healthy cells. 
Further studies are ongoing to increase the activity of the complexes 
by introducing “self-immolative” linkers
[23]
 in order to enable the 
separation of the biovector from the [(C^N^C)Au(NHC)]
+
 
pharmacophore once inside the cancer cells. 
 
Experimental Section 
 
General Remarks. Anhydrous solvents were freshly distilled from 
appropriate drying agents. 
1
H and 
13
C{
1
H} spectra were recorded 
using a Bruker Avance DPX-300 spectrometer. 
1
H NMR spectra 
(300.13 MHz) were referenced to the residual protons of the 
deuterated solvent used. 
13
C{
1
H} NMR spectra (75.47 MHz) were 
referenced internally to the D-coupled 
13
C resonances of the NMR 
solvent. Elemental analyses were carried out at London Metropolitan 
University. Compounds 1, 3, 4, 5 and the gold precursor 
(C^N
pz
^C)AuCl were synthesized following reported 
procedures.
[2c,12,24,25]
 
 
Synthesis and characterization 
 
[(C^N
pz
^N)Au(1-methyl-3-(4-carboxypentafluorophenyl)benzylbenzim
idazol-2-ylidene)] PF6 (2) 
A mixture of 1 (45 mg, 0.087 mmol) and Ag2O (20 mg, 0.087 mmol) 
was stirred in distilled dichloromethane (20 mL) at room temperature 
in the dark for 6 h. (C^N
pz
^C)AuCl (50 mg, 0.087 mmol) and KPF6 
(49 mg, 0.261 mmol) were added to the mixture and the reaction 
was stirred overnight at room temperature in the dark. The obtained 
yellow solution was filtered through Celite and the solvent was 
removed in vacuo to give a yellow film. Upon washing with light 
petroleum a yellow powder was formed which was collected and 
dried to afford the pure product (68 mg, 0.061 mmol, 70 % yield). 
Anal. Calcd for C46H39N4O2F5AuPF6 (1116.8): C, 49.47; H, 3.52; N, 
5.02. Found: C, 49.51; H, 3.37; N, 5.20. IR (cm
-1
): ν(C=O) 1760. 
1
H 
NMR (CD2Cl2, 300.13 MHz): δ 8.97 (s, 2 H, H
2
), 7.86 (d + m, 
3
JH-H = 
9.0 Hz, 4 H, H
12
 + H
15
 + H
19
),  7.75 (d + m, 
3
JH-H = 9.0 Hz, 4 H, H
5
 + 
H
13
 + H
14
), 7.43 (dd, 
3
JH-H = 9.0 Hz, 
4
JH-H = 3.0 Hz, 2 H, H
6
), 7.37 (d, 
3
JH-H = 9.0 Hz, 2 H, H
18
), 6.88 (d, 
4
JH-H = 3.0 Hz, 2 H, H
8
), 5.75 (s, 2 H, 
N-CH2), 4.15 (s, 3 H, N-CH3), 1.18 (s, 18 H, 
t
Bu). 
13
C{
1
H} NMR 
(CD2Cl2, 75.48 MHz, 293 K): δ 164.9 (s, C
9
), 163.3 (s, Ccarbene), 161.9 
(s, C=O), 158.4 (s, C
7
), 157.2 (s, C
4
), 144.7 (s, C
3
), 141.0 (s, C
20
), 
140.0 (s, C
2
), 134.8 (s, C
16
), 134.3 (s, C
11
), 133.3 (s, C
8
), 131.9 (s, 
C
19
), 129.0 (s, C
5
), 128.1 (s, C
17
), 127.5 (s, C
18
), 127.4 (s, C
13/14
), 127. 
3 (s, C
13/14
), 126.2 (s, C
6
), 113.0 (s, C
12/15
), 112.8 (s, C
12/15
), 52.3 (s, 
CH2-N), 36.8 (s, N-CH3), 35.7 (s, C(CH3)3), 31.1 (s, C(CH3)3). 
19
F{
1
H} 
NMR (CD2Cl2, 282.38 MHz, 293 K) δ -73.2 (d, 
1
JP-F = 711 Hz, 6 F, 
PF6), -153.1 (d, 
3
JF-F = 16.9 Hz, 2 F, CFortho), -158.2 (t, 
3
JF-F = 21.2 Hz, 
1 F, CFpara), -162.8 (dd, 
3
JF-F = 19.7 Hz and 22.6 Hz, 2 F, CFmeta). 
 
[(C^N
pz
^N)Au(1-methyl-3-(4-(2-aminoethyl)carboxamid)benzylbenzi
midazol-2-ylidene)]PF6 (AuC2NH2) 
A mixture of 2 (250 mg, 0.22 mmol) and ethylenediamine (0.3 mL, 
4.4 mmol) was stirred in distilled acetonitrile (20 mL) at 80 C for 3 h. 
After the solution was cooled to room temperature, acetonitrile was 
removed under vacuum, leaving an orange oily solid which was 
dissolved into dichloromethane. The organic phase was washed 
twice with a saturated aqueous NaHCO3 solution and twice with 
water. After drying over Na2SO4, the solvent was partially 
evaporated. Upon addition of light petroleum an orange precipitate 
was formed which was collected and dried to afford the pure product 
as an orange powder (208 mg, 0.21 mmol, 95 % yield). Anal. Calcd 
for C42H46N6OAuPF6 (992.8): C, 50.81; H, 4.67; N, 8.47. Found: C, 
50.69; H, 4.43; N, 8.56. IR (cm
-1
): ν(N-H) 3441, ν(N-H) 3299, ν(C=O) 
1650. 
1
H NMR (CD2Cl2, 300.13 MHz): δ 8.94 (s, 2 H, H
2
), 7.83-7-70 
(d + m, 
3
JH-H = 9.0 Hz, 6 H, H
5
 + H
13-16
), 7.52 (d, 
3
JH-H = 9.0 Hz, 2 H, 
H
19
),
 
7.40 (dd, 
3
JH-H = 9.0 Hz, 
4
JH-H = 3.0 Hz, 2 H, H
6
), 7.20 (d, 
3
JH-H = 
9.0 Hz, 3 H, H
18
 + C(O)NH), 6.89 (d, 
4
JH-H = 3.0 Hz, 2 H, H
8
), 5.67 (s, 
2 H, N-CH2), 4.13 (s, 3 H, N-CH3), 3.36 (m, 2 H, C(O)NH-CH2), 2.86 
(t, 
3
JH-H = 6.0 Hz, CH2-NH2), 2.70 (broad s, 2 H, NH2), 1.18 (s, 18 H, 
t
Bu). 
13
C{
1
H} NMR (CD2Cl2, 75.48 MHz, 293 K): δ 166.5 (s, C=O), 
165.2 (s, C
9
), 163.2 (s, Ccarbene), 158.3 (s, C
7
), 157.2 (s, C
4
), 144.8 (s, 
C
3
), 140.0 (s, C
2
), 136.9 (s, C
20
), 135.6 (s, C
17
), 134.8 (s, C
11/16
), 
134.3 (s, C
11/16
), 133.3 (s, C
8
), 128.4 (s, C
18+19
), 127.5 (s, C
5
), 127.2 
(s, C
13/14
), 127.1 (s, C
13/14
), 126.0 (s, C
6
), 113.0 (s, C
12/15
), 112.8 (s, 
C
12/15
), 52.5 (s, CH2-N), 41.3 (s, HN-CH2-CH2), 36.7 (s, N-CH3), 35.7 
(s, C(CH3)3), 31.1 (s, C(CH3)3). 
19
F{
1
H} NMR (CD2Cl2, 282.38 MHz, 
293 K) δ -73.2 (d, 
1
JP-F = 711 Hz, 6 F, PF6). 
 
[(C^N
pz
^N)Au(1-methyl-3-(4-(4-aminobutyl)carboxamid)benzylbenzi
midazol-2-ylidene)]PF6 (AuC4NH2) 
Following the procedure described for AuC2NH2, the compound was 
made from 2 (200 mg, 0.17 mmol) and 1,4-diaminobutane (302 mg, 
3.4 mmol) and obtained as an orange powder (155 mg, 0.15 mmol, 
89 % yield). Anal. Calcd for C44H50N6OAuPF6 (1020.9): C, 51.77; H, 
4.94; N, 8.23. Found: C, 51.65; H, 4.86; N, 8.31. IR (cm
-1
): ν(N-H) 
3305 (very broad), ν(C=O) 1646. 
1
H NMR (CD2Cl2, 300.13 MHz): δ 
8.97 (s, 2 H, H
2
), 7.78-7-70 (d + m, 
3
JH-H = 9.0 Hz, 6 H, H
5
 + H
13-16
), 
7.48 (d, 
3
JH-H = 9.0 Hz, 2 H, H
19
),
 
7.42 (dd, 
3
JH-H = 9.0 Hz, 
4
JH-H = 3.0 
Hz, 2 H, H
6
), 7.22 (d, 
3
JH-H = 9.0 Hz, 2 H, H
18
), 7.12 (broad t, 1 H, 
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C(O)NH), 6.91 (d, 
4
JH-H = 3.0 Hz, 2 H, H
8
), 5.69 (s, 2 H, N-CH2), 4.14 
(s, 3 H, N-CH3), 3.30 (m, 2 H, CH2
21
), 2.70 (t, 
3
JH-H = 6.0 Hz, CH2
24
), 
1.60 (m, 4 H, CH2
22
 + NH2), 1.48 (m, 2 H, CH2
23
), 1.19 (s, 18 H, 
t
Bu).
 
13
C{
1
H} NMR (CD2Cl2, 75.48 MHz, 293 K): δ 166.0 (s, C=O), 165.3 (s, 
C
9
), 163.2 (s, Ccarbene), 158.4 (s, C
7
), 157.2 (s, C
4
), 144.8 (s, C
3
), 
140.0 (s, C
2
), 136.6 (s, C
20
), 136.4 (s, C
17
), 134.9 (s, C
11/16
), 134.3 (s, 
C
11/16
), 133.3 (s, C
8
), 128.4 (s, C
18/19
), 128.3 (s, C
18/19
), 127.5 (s, C
5
), 
127.2 (s, C
13/14
), 127.1 (s, C
13/14
), 126.1 (s, C
6
), 113.1 (s, C
12/15
), 
112.9 (s, C
12/15
), 52.7 (s, CH2-N), 42.0 (s, CH2
21 + 24
), 40.3 (s, CH2
22
), 
36.7 (s, N-CH3), 35.7 (s, C(CH3)3), 31.2 (s, C(CH3)3), 27.4 (s, CH2
23
). 
19
F{
1
H} NMR (CD2Cl2, 282.38 MHz, 293 K) δ -73.2 (d, 
1
JP-F = 711 Hz, 
6 F, PF6). 
 
[(C^N
pz
^N)Au(1-methyl-3-(4-(6-aminohexyl)carboxamid)benzylbenzi
midazol-2-ylidene)]PF6 (AuC6NH2) 
Following the procedure described for AuC2NH2, the compound was 
made from 2 (153 mg, 0.13 mmol) and 1,6-diaminohexane (304 mg, 
2.6 mmol) and obtained as an orange powder (122 mg, 0.12 mmol, 
89 % yield). Anal. Calcd for C46H54N6OAuPF6 (1048.9): C, 52.67; H, 
5.19; N, 8.01. Found: C, 52.57; H, 5.31; N, 7.96. IR (cm
-1
): ν(N-H) 
3442, ν(N-H) 3309, ν(C=O) 1646. 
1
H NMR (CD2Cl2, 300.13 MHz): δ 
8.96 (s, 2 H, H
2
), 7.68-7.87 (m, 6 H, H
5
 + CH
12-15
), 7.41-7.46 (m, 4 H, 
H
6
 + H
19
), 7.24 (d, 
3
JH-H = 9.0 Hz, 2 H, H
18
), 6.90 (d, 
4
JH-H = 3.0 Hz, 2 
H, H
8
), 6.02 (broad s, 1 H, C(O)NH), 5.69 (s, 2 H, N-CH2), 4.14 (s, 3 
H, N-CH3), 3.29 (m, 2 H, CH2
21
), 3.14 (t, 
3
JH-H = 6.0 Hz, 2 H, CH2
26
), 
1.50-1.57 (m, 4 H, CH2
22
 + NH2), 1.32-1.40 (m, 6 H, CH2
23-25
) 1.19 (s, 
18 H, 
t
Bu).
 13
C{
1
H} NMR (CD2Cl2, 75.48 MHz, 293 K): δ 166.2 (s, 
C=O), 165.2 (s, C
9
), 163.2 (s, C
10
), 158.3 (s, C
7
), 157.2 (s, C
4
), 144.8 
(s, C
3
), 140.0 (s, C
2
), 136.8 (s, C
20
), 134.3 (s, C
17
), 134.2 (s, C
11/16
), 
133.3 (s, C
11/16
), 128.5 (s, C
8
), 128.3 (s, C
18/19
), 128.2 (s, C
18/19
), 
127.5 (s, C
5
), 127.2 (s, C
13/14
), 127.1 (s, C
13/14
), 126.0 (s, C
6
), 113.0 
(s, C
12/15
), 112.9 (s, C
12/15
), 52.6 (s, CH2-N), 42.3 (s, CH2
26
), 40.3 (s, 
CH2
21
),  36.7 (s, N-CH3), 35.7 (s, C(CH3)3), 31.4 (s, CH2
22
), 31.1 (s, 
C(CH3)3), 26.8 (s, CH2
23-25
). 
19
F{
1
H} NMR (CD2Cl2, 282.38 MHz, 293 
K) δ -73.2 (d, 
1
JP-F = 709 Hz, 6 F, PF6). 
 
[(C^N
pz
^N)Au(NHC-C2-biotin)]PF6 (AuC2Biot) 
AuC2NH2 (40 mg, 0.040 mmol) and Biotin-NHS (14 mg, 0.040 
mmol) were dissolved in dry DMF (0.5 mL). The reaction was stirred 
at room temperature overnight. Upon addition of diethyl ether an 
orange precipitate was formed, which was collected and 
recrystallized from a mixture dichloromethane/light petroleum to give 
the pure compound as an orange powder (49 mg, 0.039 mmol, 99 % 
yield). Anal. Calcd for C52H60N8O3SAuPF6 (1219.1): C, 51.23; H, 
4.96; N, 9.19. Found: C, 51.15; H, 4.98; N, 9.12. IR (cm
-1
): ν(N-H) 
3430, ν(N-H) 3291, ν(C=O) 1731, ν(C=O) 1704, ν(C=O) 1647. 
1
H 
NMR (CD2Cl2, 300.13 MHz): δ 8.96 (s, 2 H, H
2
), 7.84-7-70 (m, 6 H, 
H
5
 + H
13-16
), 7.53 (m + d, 
3
JH-H = 9.0 Hz, 3 H, H
19
 + NHamide),
 
7.40 (d, 
3
JH-H = 9.0 Hz, 2 H, H
6
), 7.23 (d, 
3
JH-H = 9.0 Hz, 2 H, H
18
), 6.89 (s, 3 H, 
H
8
 + NHamide), 5.97 (s, 1 H, NHurea), 5.72 (s, 2 H, N-CH2), 5.10 (s, 1 H, 
NHurea), 4.38 (s, 1 H, H
29/30
), 4.18 (s, 1 H, H
29/30
), 4.13 (s, 3 H, N-CH3), 
3.36 (s, 4 H, CH2
21 + 22
), 3.03 (s, 1 H, H
27
), 2.81 (m, 1 H, H
28
), 2.57 (d, 
3
JH-H = 15 Hz, H
28
),  2.12 (broad s, 2 H, CH2
23
), 1.77 (m, 2 H, 
CH2
24/25/26
), 1.52 (m, 2 H, CH2
24/25/26
), 1.29 (m, 2 H, CH2
24/25/26
), 1.18 
(s, 18 H, 
t
Bu). ESI-MS (MeOH), positive mode exact mass for 
[C52H60N8O3SAu]
+
 (1073.4169): measured m/z 1073.4166 [M-PF6]
+
, 
positive mode exact mass for [C52H60N8O3SAuNa]
2+
 (1096.4072): 
measured m/z 548.2024 [M-PF6+Na]
2+
. 
 
[(C^N
pz
^N)Au(NHC-C4-biotin)]PF6 (AuC4Biot) 
Following the procedure described for AuC2Biot, the compound was 
made from AuC4NH2 (40 mg, 0.039 mmol) and Biotin-NHS (14 mg, 
0.039 mmol) and obtained as a yellow powder (48 mg, 0.038 mmol, 
98 % yield). Anal. Calcd for C54H64N8O3SAuPF6.4H2O (1319.2): C, 
49.17; H, 5.50; N, 8.49. Found: C, 49.44; H, 5.05; N, 9.65. IR (cm
-1
): 
ν(N-H) 3429, ν(N-H) 3290 (very broad), ν(C=O) 1704, ν(C=O) 1642. 
1
H NMR (DMSO-6d, 300.13 MHz): δ 9.37 (s, 2 H, H
2
), 8.34 (broad s, 
1 H, NHamide), 8.03-8.09 (m, 3 H, H
13/14
 + H
19
),  7.84 (d, 
3
JH-H = 7.8 Hz, 
1 H, H
12/15
), 7.75 (broad s, 1 H, NHamide),
 
7.59-7.69 (m, 4 H, H
12/15
 + 
H
13/14
 + H
5
), 7.35-7.43 (m, 4 H, H
6
 + H
18
), 6.98 (s, 2 H, H
8
), 6.79 (s, 1 
H, NHurea), 6.69 (s, 1 H, NHurea), 5.94 (s, 2 H, N-CH2), 4.43 (m, 1 H, 
H
31/32
), 4.30 (s, 1 H, H
31/32
), 4.17 (s, 3 H, N-CH3), 3.66 (broad m, 2 H, 
CH2
21 
), 3.0 (broad m, 2 H, H
24
), 2.89 (s, 1 H, H
30
), 2.73 (s, H
30
), 2.03 
(m, 2 H, H
25
),  1.71 (broad s, 1 H, CH
29
), 1.35-1.51 (m, 10 H, CH2
22-23  
+ CH2
26-28
), 1.14 (s, 18 H, 
t
Bu). ESI-MS (MeOH), positive mode exact 
mass for [C54H64N8O3SAu]
+
 (1101.4482): measured m/z 1101.4473 
[M-PF6]
+
, positive mode exact mass for [C54H64N8O3SAuK]
2+
 
(1140.4125): measured m/z 570.2152 [M-PF6+K]
2+
. 
 
[(C^N
pz
^N)Au(NHC-C6-biotin)]PF6 (AuC6Biot) 
Following the procedure described for AuC2Biot, the compound was 
made from AuC6NH2 (40 mg, 0.038 mmol) and Biotin-NHS (13 mg, 
0.038 mmol) and obtained as a yellow powder (47 mg, 0.037 mmol, 
97 % yield). Anal. Calcd for C56H68N8O3SAuPF6.2H2O (1329.3): C, 
51.26; H, 5.61; N, 8.54. Found: C, 51.47; H, 5.94; N, 8.12. IR (cm
-1
): 
ν(N-H) 3434, ν(N-H) 3296, ν(C=O) 1702, ν(C=O) 1646. 
1
H NMR 
(DMSO-6d, 300.13 MHz): δ 10.56 (broad s, 1 H, NHamide), 9.37 (s, 2 
H, H
2
), 8.33 (broad s, 1 H, NHamide), 8.04-8.06 (m, 3 H, H
13/14
 + H
19
),  
7.84 (d, 
3
JH-H = 7.8 Hz, 1 H, H
12/15
), 7.59-7.74 (m, 4 H, H
12/15
 + H
13/14
 + 
H
5
), 7.35-7.38 (m, 4 H, H
6
 + H
18
), 6.98 (s, 2 H, H
8
), 6.43 (s, 1 H, 
NHurea), 6.37 (s, 1 H, NHurea), 5.94 (s, 2 H, N-CH2), 4.29 (m, 1 H, 
H
33/34
), 4.17 (m, 4 H, N-CH3 + H
33/34
), 3.14 (broad m, 2 H, CH2
21
), 
2.99 (broad m, 2 H, CH2
26
), 2.81 (s, 2 H, H
32
), 2.03 (m, 2 H, H
27
),  
1.63 (m, 1 H, CH
31
), 1.23-1.41 (m, 14 H, CH2
22-25 
+ CH2
28-30
), 1.14 (s, 
18 H, 
t
Bu). ESI-MS (MeOH), positive mode exact mass for 
[C56H68N8O3SAu]
+
 (1129.4795): measured m/z 1129.4784 [M-PF6]
+
, 
positive mode exact mass for [C56H68N8O3SAuNa]
2+
 (1152.4698): 
measured m/z 576.2334 [M-PF6+Na]
2+
. 
 
[(C^N
pz
^N)Au(NHC-C2-ethynylestradiol)]PF6 (AuC2Est) 
AuC2NH2 (32 mg, 0.032 mmol) and ethynylestradiol-NHS (17 mg, 
0.032 mmol) were dissolved in dry acetonitrile (1 mL) and K2CO3 (9 
mg, 0.064 mmol, 2 eq.) was added. The mixture was stirred at room 
temperature overnight. The solvent was removed under vacuum and 
the residue dissolved in dichloromethane. After filtration, the 
dichloromethane solution was concentrated under vacuum. Upon 
addition of diethyl ether a pale yellow precipitate was formed which 
was collected and recrystallized from a mixture 
dichloromethane/light petroleum to give the pure compound as a 
yellow powder (34 mg, 0.025 mmol, 76 % yield). Anal. Calcd for 
C69H74N6O4AuPF6·2H2O (1427.3): C, 58.06; H, 5.37; N, 5.89. Found: 
C, 57.99; H, 5.28; N, 6.35. IR (cm
-1
): ν(N-H) 3430, ν(N-H + O-H) 
3368 (very broad), ν(C≡C) not visible, ν(C=O) 1708. 1H NMR 
(DMSO-6d, 300.13 MHz): δ 9.36 (s, 2 H, H
2
), 9.02 (s, 1 H, OHphenol), 
8.59 (s, 1 H, NH), 8.49 (s, 1 H, NH), 8.05 (s, 3 H, CHarom.), 7.79 (d,
 
3
JH-H = 7.8 Hz,  2 H, CHarom.), 7.62 (m , 4 H, CHarom.),
 
7.37-7.47 (m, 5 
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H, CHarom.), 7.06 (d, 
3
JH-H = 7.1 Hz, 1 H, H
21
), 6.99 (s, 2 H, H
8
), 6.51 
(d, 
3
JH-H = 7.1 Hz, 1 H, H
22
), 6.44 (s, 1 H, H
23
) 5.94 (s, 2 H, N-CH2), 
5.52 (s, 1 H, OH), 4.16 (s, 3 H, N-CH3), 2.89 (s, 2 H, CH2 steroid), 1.97-
1.78 (m, 6 H, CHsteroid), 1.23-1.32 (m, 7 H, CHsteroid), 1.13 (s, 18 H, 
t
Bu), 0.82 (s, 3 H, CH3 steroid). ESI-MS (MeOH), positive mode exact 
mass for [C69H72N6O4Au]
+
 (1245.5275): measured m/z 1245.5268 
[M-PF6]
+
. 
 
[(C^N
pz
^N)Au(NHC-C4-ethynylestradiol)]PF6 (AuC4Est) 
Following the procedure described for AuC2Estra, the compound 
was made from AuC4NH2 (40 mg, 0.039 mmol), ethynylestradiol-
NHS (20 mg, 0.039 mmol) and K2CO3 (11 mg, 0.078 mmol)  and 
obtained as a yellow powder (37 mg, 0.026 mmol, 67 % yield). Anal. 
Calcd for C71H76N6O4AuPF6.8H2O (1563.5): C, 54.54; H, 5.93; N, 
5.38. Found: C, 54.56; H, 4.50; N, 5.18. IR (cm
-1
): ν(N-H, O-H) 3430, 
ν(N-H, O-H) 3311, ν(C≡C) not visible, ν(C=O) 1646. 1H NMR 
(DMSO-d6, 300.13 MHz): δ 9.36 (s, 2 H, H
2
), 9.00 (s, 1 H, OHphenol), 
8.51 (s, 1 H, NH), 8.34 (s, 1 H, NH), 8.04 (s, 3 H, CHarom.), 7.83 (m,
 
3 
H, CHarom.), 7.57-7.68 (m , 5 H, CHarom.),
 
7.47 (d, 
3
JH-H = 7.8 Hz, 1 H, 
CHBzim), 7.37 (m, 4 H, CHarom.), 7.06 (d, 
3
JH-H = 7.1 Hz, 1 H, H
21
), 6.97 
(s, 2 H, H
8
), 6.50 (d, 
3
JH-H = 7.1 Hz, 1 H, H
22
), 6.43 (s, 1 H, H
23
) 5.93 
(s, 2 H, N-CH2), 5.52 (s, 1 H, OH), 4.15 (s, 3 H, N-CH3), 3.20 (m, 4 H, 
CH2-NH), 2.73 (s, 2 H, CH2 steroid), 1.67-2.27 (m, 8 H, CHsteroid + CH2), 
1.23-1.48 (m, 9 H, CHsteroid + CH2), 1.12 (s, 18 H, 
t
Bu), 0.82 (s, 3 H, 
CH3 steroid). ESI-MS (MeOH), positive mode exact mass for 
[C71H76N6O4Au]
+
 (1273.5588): measured m/z 1273.5575 [M-PF6]
+
. 
 
 
[(C^N
pz
^N)Au(NHC-C6-ethynylestradiol)]PF6 (AuC6Est) 
Following the procedure described for AuC2Estra, the compound 
was made from AuC4NH2 (50 mg, 0.048 mmol), ethynylestradiol-
NHS (25 mg, 0.048 mmol) and K2CO3 (13 mg, 0.096 mmol) and 
obtained as a yellow powder (55 mg, 0.038 mmol, 79 % yield). Anal. 
Calcd for C73H80N6O4AuPF6 (1447.4): C, 60.58; H, 5.57; N, 5.81. 
Found: C, 60.36; H, 5.65; N, 5.96. IR (cm
-1
): ν(N-H, O-H) 3432, ν(N-
H, O-H) 3318, ν(C≡C) not visible, ν(C=O) 1646. 1H NMR (DMSO-6d, 
300.13 MHz): δ 9.35 (s, 2 H, H
2
), 9.01 (s, 1 H, OHphenol), 8.49 (s, 1 H, 
NH), 8.31 (s, 1 H, CHarom.), 8.04 (m, 3 H, CHarom.), 7.83 (m,
 
2 H, 
CHarom.), 7.37-7.68 (m , 10 H, CHarom.),
 
6.97 (s + m, 3 H, H
8
 + H
21
), 
6.51 (d, 
3
JH-H = 7.1 Hz, 1 H, H
22
), 6.43 (s, 1 H, H
23
) 5.93 (s, 2 H, N-
CH2), 5.55 (m, 2 H, OH + NH), 4.16 (s, 3 H, N-CH3), 3.15-3.23 (m, 4 
H, CH2-NH), 2.85 (m, 2 H, CH2 steroid), 1.73-1.98 (m, 6 H, CHsteroid + 
CH2), 1.22-1.41 (m, 14 H, CHsteroid + CH2), 1.13 (s, 18 H, 
t
Bu), 0.82 (s, 
3 H, CH3 steroid). ESI-MS (MeOH), positive mode exact mass for 
[C73H80N6O4Au]
+
 (1301.5901): measured m/z 1301.5887 [M-PF6]
+
. 
 
 
[(C^N
pz
^N)Au(NHC-C2-NHC-AuCl)]PF6 (AuC2Au) 
AuC2NH2 (45 mg, 0.045 mmol) and {MeBzim(Bz-4-CO2(C6F5))}AuCl 
(30 mg, 0.045 mmol, 1 eq.) were stirred in distilled acetonitrile (6 mL) 
at room temperature for 5 h in the dark. The solvent was evaporated 
and the yellow solid residue was dissolved in dichloromethane. The 
solution was washed with saturated aqueous potassium carbonate 
solution and then with water. The organic phase was dried over 
sodium sulfate. Upon addition of light petroleum a yellow precipitate 
was formed that was collected, washed twice with light petroleum 
and dried to afford the pure product as a yellow powder (21 mg, 
0.014 mmol, 95 % yield). Anal. Calcd for C58H58N8O2Au2ClPF6.C6H14 
(1473.5): C, 49.22; H, 4.78; N, 7.18. Found: C, 49.91; H, 4.29; N, 
6.96. IR (cm
-1
): ν(N-H) 3321 (very broad), ν(C=O) 1651 (broad). 
1
H 
NMR (CD2Cl2, 300.13 MHz): δ 8.88 (s, 2 H, H
2
), 7.82-7.70 (m, 8 H, 
CHarom.), 7.54-7.34 (m, 11 H, 10 CHarom. + NH), 7.27 (broad m, 1 H, 
NH), 7.21 (d, 
3
JH-H = 9.0 Hz, CHarom.), 6.83 (d, 
4
JH-H = 3.0 Hz, 2 H, H
8
), 
5.76 (s, 2 H, CH2
29
), 5.65 (s, 2 H, CH2
18
), 4.11 (s, 3 H, CH3
17
), 4.09 (s, 
3 H, CH3
36
), 3.53 (broad s, 4 H, CH2
23 + 24
), 1.15 (s, 18 H, 
t
Bu). 
13
C{
1
H} NMR (CD2Cl2, 75.48 MHz, 293 K): δ 179.6 (s, C
37
), 168.0 (s, 
C=O), 167.2 (s, C=O), 165.1 (s, C
9
), 163.4 (s, C
10
), 158.2 (s, C
7
), 
157.1 (s, C
3
), 144.8 (s, C
4
), 140.1 (s, C
2
), 139.0 (s, C
28
), 137.1 (s, 
C
19
), 135.5 (s, C
22/25
), 134.8 (s, C
22/25
), 134.7 (s, C
16/35
), 134.6 (s, 
C
16/35
), 134.3 (s, C
11
), 133.3 (s, C
30
), 133.2 (s, C
8
), 128.6 (s, CHarom.), 
128.5 (s, CHarom.), 128.2 (s, CHarom.), 127.9 (s, CHarom.), 127.6 (s, C
5
), 
127.2 (s, CHbzim.), 127.0 (s, CHbzim.), 126.0 (s, C
6
), 125.3 (s, CHbzim.), 
113.0 (s, CHbzim.), 112.8 (s, CHbzim.), 112.4 (s, CHbzim.), 112.1 (s, 
CHbzim.), 52.7 (s, CH2
29
), 52.5 (s, CH2
18
), 41.4 (s, CH2
23 + 24
), 36.7 (s, 
CH3
17
), 35.8 (s, CH3
36
), 35.7 (s, C(CH3)3), 31.1 (s, C(CH3)3). 
19
F{
1
H} 
NMR (CD2Cl2, 282.38 MHz, 293 K) δ -73.2 (d, 
1
JP-F = 711 Hz, 6 F, 
PF6). ESI-MS (MeOH), positive mode exact mass for 
[C58H58N8O2Au2Cl]
+
 (1327.3697): measured m/z 1327.3688 [M-PF6]
+
, 
positive mode exact mass for [C58H58N8O2Au2]
2+
 (1292.4014): 
measured m/z 646.1985 [M-Cl-PF6]
2+
.  
 
 
[(C^N
pz
^N)Au(NHC-C4-NHC-AuCl)]PF6 (AuC4Au) 
Following the procedure described for AuC2Au, the compound was 
made from AuC4NH2 (34 mg, 0.033 mmol) and {MeBzim(Bz-4-
CO2(C6F5))}AuCl (22 mg, 0.033 mmol) and obtained as a yellow 
powder (47 mg, 0.031 mmol, 95 % yield). Anal. Calcd for 
C60H62N8O2Au2ClPF6.7H2O (1627.7): C, 44.28; H, 4.71; N, 6.88. 
Found: C, 44.19; H, 3.57; N, 7.19. IR (cm
-1
): ν(N-H) 3330, ν(C=O) 
1646. 
1
H NMR (CD2Cl2, 300.13 MHz): δ 8.92 (s, 2 H, H
2
), 7.83-7.71 
(m, 8 H, CHarom.), 7.51-7.37 (m, 10 H, 10 CHarom.), 7.22 (d, 
3
JH-H = 9.0 
Hz, CHarom.), 6.83 (d, 
4
JH-H = 3.0 Hz, 2 H, H
8
), 6.75 (broad m, 1 H, 
NH), 6.56 (broad m, 1 H, NH), 5.74 (s, 2 H, CH2
29
), 5.67 (s, 2 H, 
CH2
18
), 4.12 (s, 3 H, CH3
17
), 4.07 (s, 3 H, CH3
36
), 3.32-3.41 (m, 4 H, 
CH2
23 + 26
), 1.59 (broad s, 4 H, CH2
24 +25
), 1.16 (s, 18 H, 
t
Bu). 
13
C{
1
H} 
NMR (CD2Cl2, 75.48 MHz, 293 K): δ 179.6 (s, C
39
), 167.2 (s, C=O), 
166.3 (s, C=O), 165.1 (s, C
9
), 163.3 (s, C
10
), 158.2 (s, C
7
), 157.2 (s, 
C
3
), 144.8 (s, C
4
), 140.1 (s, C
2
), 138.8 (s, C
30
), 136.9 (s, C
19
), 136.1 
(s, C
22/27
), 135.3 (s, C
22/27
), 134.8 (s, C
16/37
), 134.6 (s, C
16/36
), 134.3 (s, 
C
11
), 133.3 (s, C
32
), 133.2 (s, C
8
), 128.6 (s, CHarom.), 128.4 (s, 
CHarom.), 128.2 (s, CHarom.), 127.9 (s, CHarom.), 127.6 (s, C
5
), 127.2 (s, 
CHbzim.), 127.1 (s, CHbzim.), 126.0 (s, C
6
), 125.3 (s, CHbzim.), 113.0 (s, 
CHbzim.), 112.8 (s, CHbzim.), 112.4 (s, CHbzim.), 112.1 (s, CHbzim.), 52.7 
(s, CH2
31
), 52.5 (s, CH2
18
), 39.9 (s, CH2
23 + 26
), 36.7 (s, CH3
17
), 35.8 (s, 
CH3
38
), 35.7 (s, C(CH3)3), 31.2 (s, C(CH3)3), 27.3 (s, CH2
24/25
), 26.9 (s, 
CH2
24/25
). 
19
F{
1
H} NMR (CD2Cl2, 282.38 MHz, 293 K) δ -73.2 (d, 
1
JP-F 
= 711 Hz, 6 F, PF6). ESI-MS (MeOH), positive mode exact mass for 
[C60H62N8O2Au2Cl]
+
 (1355.4010): measured m/z 1327.3688 [M-PF6]
+
, 
positive mode exact mass for [C60H62N8O2Au2]
2+
 (1320.4327): 
measured m/z 660.2144 [M-Cl-PF6]
2+
. 
 
[(C^N
pz
^N)Au(NHC-C6-NHC-AuCl)]PF6 (AuC6Au) 
Following the procedure described for AuC2Au, the compound was 
made from AuC6NH2 (50 mg, 0.048 mmol, 1 eq.) and {MeBzim(Bz-
4-CO2(C6F5))}AuCl (32 mg, 0.048 mmol, 1 eq.) and obtained as a 
yellow powder (47 mg, 0.031 mmol, 95 % yield). Anal. Calcd for 
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C62H66N8O2Au2ClPF6 (1529.6): C, 48.68; H, 4.35; N, 7.33. Found: C, 
48.80; H, 4.18; N, 7.18. IR (cm
-1
): ν(N-H) 3434, ν(N-H) 3330, ν(C=O) 
1645. 
1
H NMR (CD2Cl2, 300.13 MHz): δ 8.95 (s, 2 H, H
2
), 7.83-7.68 
(m, 9 H, CHarom.), 7.51-7.35 (m, 9 H, CHarom.), 7.24 (d, 
3
JH-H = 9.0 Hz, 
2 H, CHarom.), 6.89 (s, 2 H, H
8
), 6.52 (broad m, 1 H, NH), 6.36 (broad 
m, 1 H, NH), 5.73 (s, 2 H, CH2
29
), 5.70 (s, 2 H, CH2
18
), 4.13 (s, 3 H, 
CH3
17
), 4.07 (s, 3 H, CH3
36
), 3.27-3.38 (m, 4 H, CH2
23 + 28
), 1.36-1.59 
(m, 8 H, CH2
24-27
), 1.17 (s, 18 H, 
t
Bu). 
13
C{
1
H} NMR (CD2Cl2, 75.48 
MHz, 293 K): δ 179.2 (s, C
41
), 167.0 (s, C=O), 166.3 (s, C=O), 165.1 
(s, C
9
), 163.1 (s, C
10
), 158.1 (s, C
7
), 157.1 (s, C
3
), 144.8 (s, C
4
), 
139.9 (s, C
2
), 138.5 (s, C
32
), 136.9 (s, C
19
), 136.0 (s, C
22/29
), 135.2 (s, 
C
22/29
), 134.8 (s, C
16/39
), 134.5 (s, C
16/39
), 134.2 (s, C
11
), 133.2 (s, C
8
), 
131.8 (s, C
35
), 128.4 (s, CHarom.), 128.3 (s, CHarom.), 128.0 (s, CHarom.), 
127.7 (s, CHarom.), 127.5 (s, C
5
), 127.1 (s, CHbzim.), 127.0 (s, CHbzim.), 
125.9 (s, C
6
), 125.3 (s, CHbzim.), 113.0 (s, CHbzim.), 112.8 (s, CHbzim.), 
112.3 (s, CHbzim.), 112.0 (s, CHbzim.), 52.5 (s, CH2
18 + 33
), 39.8 (s, 
CH2
23/28
), 39.6 (s, CH2
23/28
), 36.6 (s, CH3
17/40
), 35.6 (s, C(CH3)3), 31.1 
(s, C(CH3)3), 29.7 (s, CH2
24/27
), 29.6 (s, CH2
24/27
), 26.3 (s, CH2
25/26
), 
26.1 (s, CH2
25/26
). 
19
F{
1
H} NMR (CD2Cl2, 282.38 MHz, 293 K) δ -73.2 
(d, 
1
JP-F = 711 Hz, 6 F, PF6). ESI-MS (MeOH), positive mode exact 
mass for [C62H66N8O2Au2Cl]
+
 (1383.4323): measured m/z 1383.4331 
[M-PF6]
+
, positive mode exact mass for [C62H66N8O2Au2]
2+
 
(1348.4640): measured m/z 674.2313 [M-Cl-PF6]
2+
.  
 
Proliferation assay 
 
Human A549 cancer cell lines (from ECACC) were cultured in RPMI 
1640 medium with 10% fetal calf serum, 2mM L-glutamine, 100U/mL 
penicillin and 100 µg/mL streptomycin (Invitrogen). Cells were 
maintained in a humidified atmosphere at 37 °C and 5% CO2. The 
human MCF-7, MDA-MB-231, HCT116 cancer cell lines, human 
embryonic kidney HEK-293 cells and the human MRC-5 fibroblasts 
(from ECACC) were cultured in DMEM medium with 10% fetal calf 
serum, 2mM L-glutamine, 100U/mL penicillin and 100 µg/mL 
streptomycin (Invitrogen). Cells were maintained in a humidified 
atmosphere at 37 °C and 5% CO2. Inhibition of cancer cell 
proliferation was measured by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium (MTS) 
assay using the CellTiter 96 Aqueous One Solution Cell Proliferation 
Assay (Promega) and following the manufacturer’s instructions. 
Briefly, cells (8 × 10
3
/100 µL for A549, MCF-7, MDA-MB-231, 
HCT116 and HEK-293, 2 × 10
3
/100 µL for MRC-5) were seeded in 
96-well plates and left untreated or treated with 1 µL of DMSO 
(vehicle control) or 1 µL of complexes diluted in DMSO at different 
concentrations in triplicate for 72 h at 37 °C with 5% CO2. Following 
this, MTS assay reagent was added for 4 h and absorbance 
measured at 490 nm using a Polarstar Optima microplate reader 
(BMG Labtech). IC50 values were calculated using GraphPad Prism 
Version 5.0 software. 
 
Uptake study 
 
MCF-7, HCT-116 and MDA-MB-231 cells were grown in 75 cm
2
 
flasks up to 70 % of confluence in 10 mL of culture medium. 
Compounds AuC6Biot, AuC6Estra, AuC6Au and AuNHC as control 
were added to the flasks (100 µL of 1 mM solution in DMSO) and 
incubated for 6 h at 37 °C with 5% CO2. Negative controls were used 
by incubating cells with DMSO alone in the same conditions. After 
removal of the medium and washing of the cells with PBS pH 7.4, 
the cells were detached using a trypsin solution. After quenching of 
trypsin with fresh medium, centrifugation and removal of the 
supernatant, the cell pellet was resuspended into 1 mL of PBS pH 
7.4 and split into twice 500 µL for metal and protein quantification. 
The number of cells (expressed in million cells) of each sample was 
determined by measuring the protein content of the treated samples 
using a BCA assay (ThermoFischer Scientific) corrected by the 
amount of protein/10
6
 cells determined for each cell type by 
measuring the protein content of an untreated sample and divided by 
the corresponding number of cells measured with a 
hematocytometer. Microwave digestion was used to solvate the 
samples to liquid form. Nitric acid and hydrogen peroxide were used 
in a Milestone Ethos 1 microwave system using SK-10 10 place 
carousel. The digest was ramped to 200 C in 15 min holding at 200 
C for 15 min. Sample was weighed into a microwave vessel before 
digestion, and decanted and rinsed into a pre weighed PFA bottle 
after digestion. ICP-MS samples were spiked with rhodium internal 
standard and run on a Thermo X series 1 ICP-MS. Isotopes selected 
were 
63
Cu, 
65
Cu, 
107
Ag, 
109
Ag and 
197
Au. Certified standards and 
independent reference were used for accuracy. Acid blanks were run 
through the system and subtracted from sample measurements 
before corrections for dilution.  
 
FRET assay  
 
The initial FRET melting screen was performed using a fluorescence 
resonance energy transfer (FRET) DNA melting based assay. The 
sequences used was hTeloGFRET (5′-FAM-d[GGG-TTA-GGG-TTA-
GGG-TTA-GGG]-TAMRA-3′). The labelled oligonucleotides (donor 
fluorophore FAM is 6-carboxyfluorescein; acceptor fluorophore 
TAMRA is 6-carboxytetramethyl-rhodamine) were prepared as a 220 
nM solution in 10 mM sodium cacodylate buffer at pH 7.2 with 100 
mM sodium chloride and then thermally annealed. Strip-tubes 
(QIAgen) were prepared by aliquoting 20 μL of the annealed DNA, 
followed by 0.2 μL of the compound solution at a concentration of 
100 μM in DMSO. Control samples for each run were prepared with 
the same quantity of DMSO with the DNA in buffer. Fluorescence 
melt curves were determined in a QIAgen Rotor-Gene Q-series PCR 
machine, using a total reaction volume of 20 μL. Measurements 
were made with excitation at 470 nm and detection at 510 nm. Final 
analysis of the data was carried out using QIAgen Rotor-Gene Q-
series software and Origin or Excel. 
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